Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
All content curated by
Rafael Fonseca MD
Rafael Fonseca MD
Alexander van Akkooi MD, PhD, FRACS
Alexander van Akkooi MD, PhD, FRACS
See All Experts
featured
Published in Oncology

Journal Scan / Research · January 19, 2023

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Previously Treated Multiple Myeloma

Journal of Clinical Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Krisstina Gowin DO

Journal of Clinical Oncology
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
J. Clin. Oncol 2023 Jan 04;[EPub Ahead of Print], MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, N Rabin, RZ Orlowski, K Suzuki, T Plesner, SS Yoon, D Ben Yehuda, PG Richardson, H Goldschmidt, D Reece, T Ahmadi, X Qin, W Garvin Mayo, X Gai, J Carey, R Carson, P Moreau

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated